Do you want to read an article? Please log in or register.
Fluoroquinolones and isoniazid resistant TB: implications for the 2018 WHO guidance
Tuberculosis
RECOMMENDED
Related content
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis
Lancet Respir Med.
Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D
doi: 10.1016/S2213-2600
RECOMMENDED
Tuberculosis
Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med.
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH, A5312 Study Team.
doi: 10.1164/rccm.201910-1960OC.
Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries
Am J Respir Crit Care Med.
Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C
doi: 10.1164/rccm.
RECOMMENDED
Tuberculosis
High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, Hamidou-Harouna Z, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Schwoebel V, Mamadou S, Lynen L, De Jong B, Van Deun A, Decroo T
doi: 10.1183/13993003.02250-2020.
RECOMMENDED
Tuberculosis
Isoniazid Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Huang CC, Becerra MC, Calderon R, Contreras C, Galea J, Grandjean L, Lecca L, Yataco R, Zhang Z, Murray M
doi: 10.1164/rccm.201908-1576OC.
RECOMMENDED
Tuberculosis
The risk of multidrug or rifampicin-resistance in men versus women with TB
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J.
McQuaid CF, Horton KC, Dean AS, Knight GM, White RG
doi: 10.1183/13993003.00626-2020.
RECOMMENDED
Tuberculosis
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis
Am J Respir Crit Care Med.
Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T
doi: 10.1164/rccm.
Tuberculosis
Rifampin-Resistant Tuberculosis In The United States, 1998-2014
Clin Infect Dis.
Sharling L, Marks SM, Goodman M, Chorba T, Mase S
doi: 10.1093/cid/ciz491.
RECOMMENDED
Tuberculosis
Evidence-based Definition for Extensively Drug-resistant Tuberculosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Roelens M, Battista Migliori G, Rozanova L, Estill J, Campbell JR, Cegielski JP, Tiberi S, Palmero D, Fox GJ, Guglielmetti L, Sotgiu G, Brust JCM, Bang D, Lange C, Menzies D, Keiser O, Raviglione M
doi: 10.1164/rccm.202009-3527OC